TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9126796
Drug: Large-volume paracentesis
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-volume paracentesis plus intravenous albumin (6-8 g/l ascites removed)
Study: 1392697
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg i.v. infusion of alendronate over 2 hours (group A, n = 10)
Study: 1392697
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg i.v. infusion of alendronate over 24 hours (group B, n = 10)
Study: 1392697
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (A and B)
Study: 3908126
Drug: Acebutolol 400-600
Normalized name: acebutolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 400-600 mg/day
Study: 3908126
Drug: Hydrochlorothiazide 25-50
Normalized name: captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25-50 mg/day
Study: 21630032
Drug: bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (200 mg twice daily)
Study: 21857087
Drug: ω‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 fatty acids (1 g twice daily)
Study: 19215552
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) on day 1 and vaginal misoprostol (800 microg) on day 3
Study: 17126406
Drug: Creative discipline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative discipline controls (CC)
Study: 12582815
Drug: 4-h mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-h mixed AA co-infusion (120 g mixed AA: 26.4 g l-lysine + l-arginine)
Study: 12582815
Drug: 10-h mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-h mixed AA co-infusion (240 g mixed AA: 52.8 g l-lysine + l-arginine)
Study: 12582815
Drug: 4-h Lys-Arg
Normalized name: Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-h Lys-Arg co-infusion (25 g each)
Study: 12005465
Drug: No infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No infusion
Study: 12582815
Drug: 4-h mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-h mixed AA co-infusion
Study: 1833610
Drug: Oestradiol patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol patch applied for 3-5 days on 20 cm2 of skin
Study: 6231043
Drug: 4% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lignocaine spray 2 ml
Study: 6231043
Drug: Halothane (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane (0.5 or 1.5%) and thiopentone (4.5 or 10 mg kg‐1)
Study: 6231043
Drug: Thiopentone (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (higher dose)
Study: 27079247
Drug: Routinely used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routinely used chlorhexidine gluconate solutions
Study: 24048369
Drug: Combined prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined prednisolone (20 mg/day) and LMW heparin (1 mg/kg/day) starting on the first day of ovarian stimulation and one day after oocyte retrieval, respectively.
Study: 18705820
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day naloxone PR
Study: 18705820
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day naloxone PR
Study: 18705820
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day naloxone PR
Study: 18705820
Drug: 2:1 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2:1 dose ratio of oxycodone to naloxone
Study: 1499598
Drug: Moxonidine 0.2
Normalized name: moxonidine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.2 mg fasting
Study: 6670341
Drug: Regular, non
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular, non medicamentous individual treatment in group A
Study: 27484299
Drug: Long-stay group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-stay group (6 months inpatient + 6 monthly return visits)
Study: 20681279
Drug: Wuzi Yanzong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuzi Yanzong Pill (WYP) for 3 months
Study: 11781402
Drug: Valacyclovir (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (1 gram, three times daily for 24 weeks)
Study: 8540716
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily) plus streptomycin (1 g/day, intramuscularly for 14 days)
Study: 8540716
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily) plus rifampin (900 mg/day, single morning dose for 45 days)
Study: 1771284
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin 2 micrograms/kg
Study: 6167119
Drug: Tetracycline chloride
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline chloride 1 g/day for one week
Study: 30932750
Drug: Montmorency cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency cherry (MC) supplement
Study: 30932750
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) supplement
Study: 31801326
Drug: Diabetes specific
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes specific nutrition supplement (DSNS) along with lifestyle intervention
Study: 23630119
Drug: l-dopa/carbidopa (LC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-dopa/carbidopa (LC)
Study: 23630119
Drug: l-dopa dose
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-dopa dose
Study: 19062112
Drug: Normal Sodium
Normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Sodium Intake (NSI) - 80 mmol/day of oral sodium supplements
Study: 8378155
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine at a dose of 6 mg/kg
Study: 8378155
Drug: Oral meperidine/promethazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meperidine/promethazine combination at doses of 2 mg/kg and 0.5 mg/kg respectively
Study: 8931526
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments combined
Study: 26771908
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) and aspirin
Study: 30344063
Drug: Aspirin only
Normalized name: Aspirin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin only
Study: 23786503
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% nicotinamide
Study: 21955937
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg extended-release niacin for 4 weeks, then 1000 mg extended-release niacin for 4 weeks
Study: 7641719
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with 4% lignocaine
Study: 31226187
Drug: Computer-assisted implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted implant planning and template-guided implant placement (CAIPP)
Study: 29121061
Drug: Chloroquine 2500
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 2500 mg total dose (1500 mg chloroquine base) over 3 days plus primaquine 15 mg daily for 14 days
Study: 29121061
Drug: Tafenoquine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 400 mg once daily for 3 days
Study: 25803763
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy management reconciliation service (MRS)
Study: 19000538
Drug: Azelnidipine 8
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 8 mg/day
Study: 21471671
Drug: Azelnidipine 16
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 16 mg/day
Study: 16838827
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg to 40 mg daily plus IPT 1 session weekly
Study: 16838827
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg to 40 mg daily
Study: 12636462
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus exercise (n = 266)
Study: 12636462
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) alone (n = 286)
Study: 12636462
Drug: Exercise alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise alone or in combination with CBT
Study: 8217759
Drug: Naftifine (Exoderil)
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine (Exoderil) applied twice daily for 4 weeks
Study: 8217759
Drug: 1% clotrimazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% clotrimazole plus 1% hydrocortisone (CHC; Canesten HC) applied twice daily for 4 weeks
Study: 6641092
Drug: Alinidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine (40 mg three times a day)
Study: 3330524
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and atropine (0.2 mg kg‐1 and 0.04 mg kg‐1 respectively)
Study: 31996370
Drug: PSA 1.01-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA 1.01-2.5 ng/mL
Study: 31996370
Drug: PSA ≤
Normalized name: Prostate-Specific Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA ≤ 0.5 ng/mL, aged ≥65 years
Study: 16143120
Drug: Certolizumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certolizumab 400 mg
Study: 26718934
Drug: Ammonia inhalation
Normalized name: ammonia INHALATION SPIRIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammonia inhalation
Study: 17689192
Drug: Hypnosis (highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis (highly hypnotic susceptible patients)
Study: 2893635
Drug: Atenolol 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25, 50 and 100 mg
Study: 2893635
Drug: Koe 3290
Normalized name: Koelers grass pollen extract
DrugBank: Koeleria macrantha pollen (DB10949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Koe 3290 12.5, 25, 50 and 100 mg
Study: 25551814
Drug: Thoracic paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic paravertebral block with 150 mg levobupivacaine
Study: 22038338
Drug: Internet training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet training (behaviorally focused and video-based training, 2 weekly visits)
Study: 18950331
Drug: Caudal blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal blockade with levobupivacaine 0.25% 2 mg x kg(‐1)
Study: 16022917
Drug: Vinorelbine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 30 mg/m² with Carboplatin (VC)
Study: 16022917
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m² with Gemcitabine (VG)
Study: 18442449
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 microg once daily
Study: 10505557
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin plus intermittent IP vancomycin
Study: 8089288
Drug: Interferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2a (3 MU subcutaneously three times per week, increased to 12 MU, total dose of 216 MU over 2 months)
Study: 57444
Drug: Fractionated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fractionated insulin preparations (Nordisk Insulin Ltd)
Study: 30506579
Drug: KCl infusion
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KCl infusion in quiescent muscle
Study: 28984822
Drug: Walnut-enriched diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-enriched diet (43 g walnuts/day)
Study: 26039534
Drug: Candesartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan treatment for 7 days, lowering blood pressure by 5/2 mmHg from day 2 onwards.
Study: 23672632
Drug: placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo added to metformin and sulphonylurea
Study: 18569468
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (Enoxaparin sodium 0.2 ml, 20 mg, once daily subcutaneously)
Study: 18569468
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (folic acid tablets 0.5 mg daily until 13 weeks gestation)
Study: 17127550
Drug: Adrenergic blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic blockers
Study: 14679156
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily tobramycin (n = 29)
Study: 11313659
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid - 300 mg/day for 28 days
Study: 11313659
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - twice a day for 28 days
Study: 1610866
Drug: OKT3, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3, 5 mg/day for 7 days
Study: 1610866
Drug: ALG, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALG, 15 mg/kg/day for 7 days
Study: 20934559
Drug: Darapladib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darapladib (160 mg enteric-coated tablets)
Study: 7789626
Drug: Insulin-modified frequently
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT)
Study: 2192563
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg/day) plus behavior modification
Study: 14722148
Drug: DSEC (dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSEC (dietary supplement containing ephedra [12 mg] and caffeine [40 mg])
Study: 15457926
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei DN114001 fermented milk (10(8)-10(10) ufc/g), 3 cups per day for 8 weeks
Study: 9777137
Drug: Hirudin treatment
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin treatment in patients with ST elevation receiving thrombolytic therapy (TIMI 9)
Study: 9777137
Drug: Hirudin treatment
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin treatment in the full spectrum of acute coronary syndromes (GUSTO 2)
Study: 7932515
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 micrograms oral dose
Study: 2892768
Drug: Nizatidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (300 mg 'nocte')
Study: 2892768
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg 'nocte')
Study: 27302544
Drug: Telephone-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive-behavioural therapy
Study: 22978615
Drug: Diamel (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamel (two capsules before each of the three main meals daily for 1 year)
Study: 22978615
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules before each of the three main meals daily for 1 year)
Study: 11905457
Drug: Minimum therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum therapy at presentation plus maximum therapy at local relapse
Study: 9654538
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg once daily, subcutaneously for not less than seven days)
Study: 189385
Drug: Terbutaline 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.25 mg
Study: 26665978
Drug: EOB body
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOB body cream
Study: 21807659
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g dark chocolate (>85% cocoa)
Study: 19494810
Drug: Atorvastatin (20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20‐80 mg) before and after gastric bypass surgery
Study: 11008908
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg per day
Study: 8270392
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefuroxime (1.5 g i.v. on call to surgery)
Study: 25102877
Drug: Aspirin continuation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin continuation (100mg/d)
Study: 25102877
Drug: Aspirin withdrawal
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin withdrawal 3 days pre-extraction
Study: 25102877
Drug: Aspirin withdrawal
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin withdrawal 5 days pre-extraction
Study: 22018760
Drug: Dolutegravir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (all doses combined)
Study: 10624993
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine 0.15 mg/kg after induction and normal saline at the end of surgery (PRE group)
Study: 9098871
Drug: 0.12% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% betamethasone 17-valerate cream formulation
Study: 27372742
Drug: Caffeine (CAF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAF, 6 mg kg(‐1))
Study: 20558830
Drug: Intensive motor
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive motor training program (n=30) with 3 sessions of physical therapy and a structured home exercise program for 4 weeks after discharge.
Study: 20558830
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (n=32).
Study: 10430197
Drug: Indomethacin tocolysis
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin tocolysis (50 mg followed by 25 mg 6 hourly for 48 hours)
Study: 31182047
Drug: Structured skills
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured skills training group (SSTG) based on dialectical behaviour therapy (DBT)
Study: 17548076
Drug: Metformin 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2000 mg/day
Study: 12817827
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day ethanol
Study: 9277075
Drug: Isoflurane with
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane with thiopental (3‐5 mg/kg for induction), succinylcholine (1‐2 mg/kg for intubation), and vecuronium as a muscle relaxant
Study: 23287080
Drug: Dobutamine 5
Normalized name: dobutamine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine 5 μg/kg/min
Study: 18179368
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine solution
Study: 27052531
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid 800 μg/d
Study: 27052531
Drug: Creatine 3
Normalized name: Creatine 3200 MG Oral Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine 3 g/d
Study: 16436724
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg b.i.d. (after 9 doses of 200 mg q.i.d.)
Study: 16436724
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg b.i.d. (after 9 doses of 400 mg q.i.d.)
Study: 16436724
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg q.d. (after 5 doses of 800 mg b.i.d.)
Study: 16436724
Drug: Overall mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall mean exposure of 400 mg b.i.d.
Study: 16436724
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events leading to premature discontinuation
Study: 10618936
Drug: Intra-articular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular morphine 2 mg
Study: 26552352
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) effervescent tablets, daily dose based on weight, for 5 days
Study: 23299767
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (6 mg · kg(‐1) body weight, n = 17)
Study: 2344697
Drug: D-propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-propranolol (120 mg for 5 days)
Study: 2344697
Drug: L-propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propranolol (120 mg for 5 days)
Study: 28274276
Drug: L-citrulline for
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline for 24 weeks
Study: 24113042
Drug: Ambrisentan 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 2.5 mg or 5 mg once daily for 12 weeks
Study: 10577447
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg frusemide twice a day
Study: 1282465
Drug: Loxiglumide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (10 mg kg‐1 h‐1)
Study: 1752290
Drug: Bile acids
Normalized name: Conjugated bile acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile acids (2 g ursodeoxycholic acid plus 2 g chenodeoxycholic acid)
Study: 7005678
Drug: Prednisolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (15 to 20 mg per day, maintenance dosage 10 mg per day)
Study: 24239881
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation + Physical Therapy (PT)